国际新闻精选周三（2017年1月18日）

The top 15 best-selling cancer drugs in 2022

If there was any doubt that the oncology market is set to reach unprecedented heights, FiercePharma's top 15 list of cancer drugs in 2022 should eliminate it.

All told, by 2022, the top 15 cancer drugs are expected to collectively make almost $90 billion in sales. To put that in perspective, that represents about one-fourth of the entire U.S. pharma market in 2014, according to QuintilesIMS data. It's also bigger than pharma's haul in Japan or China that year.【阅读全文】

M&A in 2016: Pause for breath in a shifting market

Are pharma groups biding their time or exercising caution? This is the question that needs to be asked when looking at 2016’s M&A totals, which fell back substantially from the free-spending days of 2014 and 2015.The $98.7bn spent on acquisitions in 2016 was less than half that of the biotech boom’s peak in 2014 even though many biotech targets became more affordable as their valuations tumbled through the course of the year.【阅读全文】

Where the money is, 2016 edition: The top 100 VCs investing in biotech, by the numbers

Using the latest set of numbers on the top 100 VCs operating in the US, you can sketch out all of the big trends at play in the multibillion-dollar game of biotech investing and startups.

The top four VCs - Flagship, Third Rock, New Enterprise Associates and Arch Venture - all entered 2016 flush with cash and ready to start ramping up new companies while fostering the upstarts already in their portfolios, according to figures Thomson Reuters provided to Endpoints News. NEA may have slipped down the list a bit, but the life sciences group under David Mott continues to be one of the most prolific in the industry, not shy in the least to take a lead role in big new rounds.【阅读全文】

This year’s JPM roundup: deals, lack of deals, a different breed of startup, and a Trump card

The J.P. Morgan event is known as the event for biotech and the investor community and, although typically aimed at generalists, bio journalists are always on the lookout for deals, critical updates, and using the conference as a litmus test for what the year ahead may bring. We got a taste of that with a series of deals, many from Japan (and in fact Takeda taking much of the weight in that regard) with U.S. biotechs, but the one big deal that many lined up to see—one from Gilead—never materialized.【阅读全文】

The Stem-Cell Revolution Is Coming — Slowly

I interviewed him recently in San Francisco. Our conversation has been edited for length and clarity. Continue reading the main story Q. There has been great enthusiasm and confidence for nearly 20 years that the use of stem cells will lead to powerful new treatments for a range of diseases. Now, 10 years after your discovery, what treatments have been developed?【阅读全文】

Alcobra blasted by a PhIII flop for ADHD drug as its options dwindle

You can turn out the lights at Alcobra. The party is over, and it ended badly. This morning the Israeli biotech $ADHD revealed that its Phase III study of MDX flopped. The drug failed to distinguish itself from a placebo, and the company will now start considering the strategic options left to it as a result.【阅读全文】

AstraZeneca expands 1st-line lung cancer Immuno-Oncology programme opportunities

AstraZeneca today provides an update on its Immuno-Oncology (IO) late-stage clinical development programme in 1st-line non-small cell lung cancer (NSCLC), including a refinement of the Phase III MYSTIC trial.

The MYSTIC trial was initially designed to assess the benefit of durvalumab monotherapy and durvalumab and tremelimumab (durva + treme) combination therapy versus standard-of-care (SoC) chemotherapy, focused on progression-free survival (PFS).【阅读全文】

Five-tiered Gleason grouping system predicts prostate cancer mortality

Researchers successfully validated the five-tiered Gleason Grade Grouping system for predicting mortality among men with prostate cancer, according to results of a population-based study.“Our study, based on broad representation of racially diversified populations, is the first one to demonstrate that this new [five]-tiered Gleason Grade Grouping system is a powerful predictor of prostate cancer–specific mortality across different cancer stages and cancer therapies and can serve as the cornerstone of risk stratification to guide treatment decisions,” Grace Lu-Yao, PhD, MPH, associate director for population science at Sidney Kimmel Cancer Center of Thomas Jefferson University, told HemOnc Today.【阅读全文】

XBiotech Phase 3 Data for Colorectal Cancer Therapy is Published in The Lancet Oncology

XBiotech Inc. (NASDAQ:XBIT) today announced the publication of results from its pivotal phase 3 trial of the Company’s lead monoclonal antibody therapy. The results were published in The Lancet Oncology in an article titled, “MABp1 as a Novel Antibody Treatment for Advanced Colorectal Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study.” The article is now available online.【阅读全文】

Cisplatin-Based Chemotherapy Increases Risk of Venous Thromboembolism

The risk of venous thromboembolism (VTE)—formation of a blood clot in the vein—in patients with cancer is known to be significantly higher compared with the general population. Now, a new study has found that in addition to tumor type, stage, and the presence of comorbidities, patients receiving cisplatin-based treatments might be at an increased risk of VTE.【阅读全文】

Tesaro Announces Opening of Niraparib Expanded Access Program for U.S. Patients With Ovarian Cancer

TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the opening of an expanded access program (EAP) in the United States for the investigational PARP inhibitor, niraparib. Through this program, niraparib is being made available for eligible women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer following a complete or partial response to platinum-based chemotherapy. Healthcare professionals can learn more about the niraparib EAP by visiting www.niraparibEAP.com. An EAP for niraparib in Europe is planned to open in the first half of 2017, and will be initiated on a country-by-country basis.【阅读全文】

★ 请关注《美中药源》微信公众号 ★